Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 1
1989 1
2003 2
2004 1
2006 3
2007 3
2008 6
2009 3
2010 4
2011 4
2012 3
2013 3
2014 1
2015 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G. Tarantino P, et al. Among authors: koutras ak. Ann Oncol. 2023 Aug;34(8):645-659. doi: 10.1016/j.annonc.2023.05.008. Epub 2023 Jun 1. Ann Oncol. 2023. PMID: 37269905 Review.
Bevacizumab in the treatment of breast cancer.
Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP. Koutras AK, et al. Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22. Cancer Treat Rev. 2010. PMID: 19932567 Review.
Angiogenesis as a therapeutic target in breast cancer.
Koutras AK, Starakis I, Lymperatou D, Kalofonos HP. Koutras AK, et al. Mini Rev Med Chem. 2012 Oct;12(12):1230-8. doi: 10.2174/138955712802761988. Mini Rev Med Chem. 2012. PMID: 22512568 Review.
The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. Koutras AK, et al. Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Crit Rev Oncol Hematol. 2010. PMID: 19481955 Review.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Koutras AK, et al. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. Pharmacogenomics J. 2012. PMID: 21844885 Clinical Trial.
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P. Fountzilas G, et al. Among authors: koutras ak. Cancer Invest. 2008 Oct;26(8):784-93. doi: 10.1080/07357900801918611. Cancer Invest. 2008. PMID: 18798073 Clinical Trial.
33 results